United Therapeutics (NASDAQ:UTHR) CFO Sells $5,491,700.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $549.17, for a total transaction of $5,491,700.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,366,132.92. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

James Edgemond also recently made the following trade(s):

• On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00.
• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.50, for a total transaction of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.87, for a total transaction of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total transaction of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total transaction of $5,730,300.00.

United Therapeutics Price Performance

UTHR stock traded down $1.48 during trading on Tuesday, reaching $548.09. 595,791 shares of the company were exchanged, compared to its average volume of 479,066. The company has a 50-day moving average of $566.45 and a two-hundred day moving average of $522.10. The company has a market capitalization of $23.27 billion, a price-to-earnings ratio of 20.23, a P/E/G ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the company earned $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on UTHR. HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Cantor Fitzgerald increased their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Leuthold Group LLC raised its stake in United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares in the last quarter. Tobam increased its stake in shares of United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after buying an additional 4,953 shares during the period. UBS Group AG increased its stake in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after buying an additional 70,445 shares during the period. Perpetual Ltd purchased a new position in shares of United Therapeutics in the fourth quarter worth $1,059,000. Finally, SG Americas Securities LLC boosted its holdings in United Therapeutics by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after acquiring an additional 12,663 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.